Altogether, these data indicate non-oncogene addiction for the SUMO pathway of Myc-driven lymphoma and point to the SUMO pathway as a novel potential pharmacological target to treat this cancer [89] (Figure 4). The gene discussed is MYC; the disease is lymphoma.